Associations of Cyclooxygenase 2 polymorphic genotypes with bladder cancer risk in Taiwan

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5401-5405

  Chang, Wen Shin ^a,b   Tsai, Chia Wen ^a,b   Ji, Hong Xue ^a,b   Wu, Hsi Chin ^b   Chang, YI Ting ^a,b   Lien, Chi Shun ^b   Liao, Wen Ling ^b   Shen, WU Chung ^a   Tsai, Chang Hai ^b   Bau, DA Tian ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bladder cancer; Cox 2; Genotype; Polymorphism

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; ALLELE; ARTICLE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TAIWAN;

EID: 84891407086     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Franekova M, Halasova E, Bukovska E, Luptak J and Dobrota D: Gene polymorphisms in bladder cancer. Urol Oncol 26: 1-8, 2008.
2. Wang YH, Lee YH, Tseng PT, Shen CH and Chiou HY: Human NAD(P)H:quinone oxidoreductase 1 (NQO1) and sulfotransferase 1A1 (SULT1A1) polymorphisms and urothelial cancer risk in Taiwan. J Cancer Res Clin Oncol 134: 203-209, 2008.
3. Steineck G, Wiholm BE and Gerhardsson de Verdier M: Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol 34: 741-748, 1995.
4. Cohen SM, Shirai T and Steineck G: Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl: 105-115, 2000.
5. DeWitt DL: Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1083: 121-134, 1991.
6. Kujubu DA, Reddy ST, Fletcher BS and Herschman HR: Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem 268: 5425-5430, 1993.
7. Kawata R, Reddy ST, Wolner B and Herschman HR: Prostaglandin synthase 1 and prostaglandin synthase 2 both participate in activation-induced prostaglandin D2 production in mast cells. J Immunol 155: 818-825, 1995.
8. Reddy ST and Herschman HR: Ligand-induced prostaglandin synthesis requires expression of the TIS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 269: 15473-15480, 1994.
9. Fujimura T, Ohta T, Oyama K, Miyashita T and Miwa K: Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 12: 1336-1345, 2006.
10. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Ziogas A and Ross RK: Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97: 805-812, 2005.
11. van Rees BP and Ristimaki A: Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 36: 897-903, 2001.
12. Wang W, Bergh A and Damber JE: Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11: 3250-3256, 2005.
13. Cok SJ and Morrison AR: The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 276: 23179-23185, 2001.
14. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE and Laurent GJ: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22: 1631-1636, 2002.
15. Kang S, Kim YB, Kim MH, Yoon KS, Kim JW, Park NH, Song YS, Kang D, Yoo KY, Kang SB and Lee HP: Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett 217: 11-16, 2005.
16. Baris D, Karagas MR, Koutros S, Colt JS, Johnson A, Schwenn M, Fischer AH, Figueroa JD, Berndt SI, Han S, Beane Freeman LE, Lubin JH, Cherala S, Cantor KP, Jacobs K, Chanock S, Chatterjee N, Rothman N and Silverman DT: Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England. Int J Cancer 132: 162-173, 2013.
17. Gangwar R, Mandhani A and Mittal RD: Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery 149: 126-134, 2011.
18. Hsia TC, Tsai CW, Liang SJ, Chang WS, Lin LY, Chen WC, Tu CY, Tsai CH and Bau DT: Effects of ataxia telangiectasia mutated (ATM) genotypes and smoking habits on lung cancer risk in Taiwan. Anticancer Res 33: 4067-4071, 2013.
19. Tsai CW, Tsai MH, Shih LC, Chang WS, Lin CC and Bau DT: Association of interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan. Anticancer Res 33: 3391-3396, 2013.
20. Chang WS, Ke HL, Tsai CW, Lien CS, Liao WL, Lin HH, Lee MH, Wu HC, Chang CH, Chen CC, Lee HZ and Bau DT: The role of XRCC6 T-991C functional polymorphism in renal cell carcinoma. Anticancer Res 32: 3855-3860, 2012.
21. Chang WS, Yang MD, Tsai CW, Cheng LH, Jeng LB, Lo WC, Lin CH, Huang CY and Bau DT: Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in Taiwan. Chin J Physiol 55: 1-7, 2012.
22. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G and Witte JS: COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97: 557-561, 2007.
23. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W and Kittles RA: COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25: 961-966, 2004.
24. Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang BL, Adami HO, Liu W, Gronberg H and Xu J: Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119: 668-672, 2006.
25. Fernandez P, de Beer PM, van der Merwe L and Heyns CF: COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis 29: 2347-2350, 2008.
26. Wu HC, Chang CH, Ke HL, Chang WS, Cheng HN, Lin HH, Wu CY, Tsai CW, Tsai RY, Lo WC and Bau DT: Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in taiwan. Anticancer Res 31: 221-225, 2011.
27. Mandal RK and Mittal RD: Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort. Arch Med Res 42: 620-626, 2011.